Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Non-Current Liabilities (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 65.22% to $4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0 million, a 65.22% decrease, with the full-year FY2025 number at $4.0 million, down 65.22% from a year prior.
  • Other Non-Current Liabilities was $4.0 million for Q4 2025 at Phathom Pharmaceuticals, down from $11.5 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $11.5 million in Q4 2024 to a low of $4.0 million in Q4 2025.
  • A 4-year average of $8.9 million and a median of $8.6 million in 2022 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: skyrocketed 43.33% in 2024, then tumbled 65.22% in 2025.
  • Phathom Pharmaceuticals' Other Non-Current Liabilities stood at $7.5 million in 2022, then rose by 29.33% to $9.7 million in 2023, then grew by 18.56% to $11.5 million in 2024, then crashed by 65.22% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Other Non-Current Liabilities are $4.0 million (Q4 2025), $11.5 million (Q3 2025), and $11.5 million (Q2 2025).